Omni Bio Pharmaceutical, Inc. has got the US patent for its product useful in the treatment of anthrax infection. The US patent titled as "Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections," was issued by the United States Patent and Trademark Office.
The US patent no 7,850,970 is the result of joint efforts form Omni Bio and University of Colorado Denver under a licence agreement between them. This patent covers inhibition of all forms of Bacillus anthracis infection which is commonly known as anthrax by using one or more of four new peptides made up of 10 linked amino acids.
No comments:
Post a Comment